BI-655064

N/A

Report date: 2026/03/23 20:03:44

Base Information

Drug NameBI-655064
Drug Alias NameBI-655064
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionTumor necrosis factor receptor superfamily member 5 inhibitors
TargetsTumor necrosis factor receptor superfamily member 5
Therapy Area/IndicationsPurpura, Thrombocytopenic, IdiopathicLupus NephritisArthritis, Rheumatoid
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaCanadaUnited States +[22] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesC.H. Boehringer Sohn Ag & Co. Kg
China Registration ClassN/A

Develop Information

Active CompaniesC.H. Boehringer Sohn Ag & Co. Kg
Inactive CompaniesN/A
Active IndicationsLupus Nephritis
Inactive IndicationsPurpura, Thrombocytopenic, IdiopathicArthritis, Rheumatoid

Other Information

ATC CodeN/A
Related LinksN/A